flecainide has been researched along with Parkinson Disease in 1 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Excessive daytime sleepiness (EDS) is a frequent and disabling symptom of Parkinson's disease (PD) without approved treatment." | 3.11 | THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. ( Azulay, JP; Bosse, B; Corvol, JC; Dauvilliers, Y; Defebvre, L; Klostermann, F; Kovacs, N; Maltête, D; Ondo, WG; Pahwa, R; Rascol, O; Rein, W; Thobois, S; Valis, M; Videnovic, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corvol, JC | 1 |
| Azulay, JP | 1 |
| Bosse, B | 1 |
| Dauvilliers, Y | 1 |
| Defebvre, L | 1 |
| Klostermann, F | 1 |
| Kovacs, N | 1 |
| Maltête, D | 1 |
| Ondo, WG | 1 |
| Pahwa, R | 1 |
| Rein, W | 1 |
| Thobois, S | 1 |
| Valis, M | 1 |
| Videnovic, A | 1 |
| Rascol, O | 1 |
1 trial available for flecainide and Parkinson Disease
| Article | Year |
|---|---|
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
Topics: Disorders of Excessive Somnolence; Double-Blind Method; Drug Combinations; Flecainide; Humans; Modaf | 2022 |